Here's my summary of key studies presented Tuesday.
Tofacitinib in Polyarticular JIA
Shingrix (GSK), the herpes zoster subunit vaccine (a two-shot series), was approved by the FDA in Fall 2018 and is currently approved for use in adults 50 years and older.
It has been a wonderful year for autoinflammatory diseases at the ACR Annual Meeting.
“If exercise could be purchased in a pill, it would be the single most widely prescribed and beneficial medicine in the nation.” —Robert H. Butler, MD, first director of the National Institute on Aging.